Literature DB >> 8486533

Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5'-deoxy-5-fluorouridine.

H Eda1, K Fujimoto, S Watanabe, T Ishikawa, T Ohiwa, K Tatsuno, Y Tanaka, H Ishitsuka.   

Abstract

The antiproliferative activity of 5-fluorouracil (5-FUra) and 5'-deoxy-5-fluorouridine (5'-dFUrd), used in combination with typical cytokines and growth factors, was investigated in mouse colon 26 carcinoma cells. Tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon gamma (IFN gamma) at low doses showing < 50% inhibition of cell growth by themselves enhanced the susceptibility of the cells to the activity of 5'-dFUrd. In particular, a mixture of these cytokines greatly enhanced the activity of 5'-dFUrd and 5-FUra by up to 12.4- and 2.7-fold, respectively, whereas the activity of other cytostatics was only slightly changed (< 1.5-fold). Basic fibroblast growth factor also increased the susceptibility, but only to 5'-dFUrd. This preferential enhancement of the activity of 5'-dFUrd would be due to induction by the cytokines of uridine phosphorylase (Urd Pase), by which 5'-dFUrd is converted to 5-FUra. TNF alpha, IL-1 alpha, IFN gamma, and a mixture of these factors increased the enzyme activity by up to 3.7-fold in colon 26 cells. Consequently, the anabolism of 5'-dFUrd to fluoronucleotides and the incorporation of 5-FUra into RNA in colon 26 cells were increased by TNF alpha treatment. In addition, the increase by the cytokine mixture in the susceptibility to 5'-dFUrd was abolished by an inhibitor of Urd Pase, 2,2'-anhydro-5-ethyluridine. These results indicate that induction of Urd Pase activity by cytokines is a critical event that increases the susceptibility to 5'-dFUrd.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486533      PMCID: PMC5919148          DOI: 10.1111/j.1349-7006.1993.tb02876.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  32 in total

1.  Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.

Authors:  A Kono; Y Hara; S Sugata; Y Karube; Y Matsushima; H Ishitsuka
Journal:  Chem Pharm Bull (Tokyo)       Date:  1983-01       Impact factor: 1.645

2.  5-Substituted-2,2'-anhydrouridines, potent inhibitors of uridine phosphorylase.

Authors:  Z Veres; A Szabolcs; I Szinai; G Dénes; M Kajtár-Peredy; L Otvös
Journal:  Biochem Pharmacol       Date:  1985-05-15       Impact factor: 5.858

3.  The efficacy of combined treatment with recombinant human tumor necrosis factor-alpha and 5-fluorouracil is dependent on the development of capillaries in tumor.

Authors:  T Manda; F Nishigaki; S Mukumoto; K Masuda; T Nakamura; K Shimomura
Journal:  Eur J Cancer       Date:  1990-02       Impact factor: 9.162

4.  New combination of 5-fluorouracil and interferon-gamma effective against human myeloid leukemia in vitro.

Authors:  M Kafka; I Nathan; A Dvilansky
Journal:  Anticancer Res       Date:  1989 Jul-Aug       Impact factor: 2.480

5.  Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon.

Authors:  G Tisman; S J Wu
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

6.  Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

7.  Interactions of interferon-alpha 2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro.

Authors:  H T Tevaearai; P L Laurent; L Suardet; J F Eliason; J C Givel; N Odartchenko
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

8.  Activation and cytotoxicity of 5'-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells.

Authors:  Y Geng; E Gheuens; E A de Bruijn
Journal:  Biochem Pharmacol       Date:  1991-01-15       Impact factor: 5.858

Review 9.  Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.

Authors:  S G Arbuck
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

10.  Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil.

Authors:  Y Ohta; K Sueki; K Kitta; K Takemoto; H Ishitsuka; Y Yagi
Journal:  Gan       Date:  1980-04
View more
  6 in total

1.  Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.

Authors:  Deliang Cao; Amy Ziemba; James McCabe; Ruilan Yan; Laxiang Wan; Bradford Kim; Michael Gach; Stuart Flynn; Giuseppe Pizzorno
Journal:  Mol Cancer Ther       Date:  2011-09-27       Impact factor: 6.261

Review 2.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

Review 3.  Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.

Authors:  L Griffiths; I J Stratford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.

Authors:  M Ueda; H Fujii; K Yoshizawa; K Kumagai; K Ueki; Y Terai; T Yanagihara; M Ueki
Journal:  Jpn J Cancer Res       Date:  1998-12

5.  Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

Authors:  K Midoro; K Gotoh; T Houkan; K Yukishige; K Fujiwara; K Ootsu
Journal:  Jpn J Cancer Res       Date:  1997-03

6.  Increased hepatic nicotinamide N-methyltransferase activity as a marker of cancer cachexia in mice bearing colon 26 adenocarcinoma.

Authors:  A Okamura; Y Ohmura; M M Islam; M Tagawa; K Horitsu; Y Moriyama; S Fujimura
Journal:  Jpn J Cancer Res       Date:  1998-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.